pembrolizumab + rituximab + obinutuzumab

This combination therapy involves the PD-1 inhibitor pembrolizumab administered alongside anti-CD20 monoclonal antibodies, specifically rituximab or obinutuzumab. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between the Programmed cell death protein 1 (PD-1) receptor and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell mediated anti-tumor immune responses. Rituximab and obinutuzumab are monoclonal antibodies targeting the CD20 antigen on B-cells, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The University of Washington evaluated this combination in a Phase II clinical trial (NCT03401853) for patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. Results from the study indicated that while the regimen was tolerable, it demonstrated limited clinical efficacy in these specific lymphoma populations.

Brand names

KeytrudaRituxanGazyva

Other names

Pembrolizumab plus anti-CD20 antibodyPembrolizumab with rituximab or obinutuzumab